Gossamer Bio logo

Gossamer BioNASDAQ: GOSS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 February 2019

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$161.68 M
-88%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector
-88%vs. 3y high
68%vs. sector
-48%vs. 3y high
32%vs. sector

Price

after hours | Sat, 23 Nov 2024 00:54:49 GMT
$0.71+$0.03(+4.65%)

Dividend

No data over the past 3 years
$9.48 M$6.83 M
$9.48 M-$30.80 M

Analysts recommendations

Institutional Ownership

GOSS Latest News

All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy
zacks.com21 November 2024 Sentiment: POSITIVE

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
zacks.com15 November 2024 Sentiment: POSITIVE

Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
zacks.com14 November 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.

3 Penny Stocks To Buy With Just $50
247wallst.com15 September 2024 Sentiment: POSITIVE

Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
seekingalpha.com10 September 2024 Sentiment: POSITIVE

Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
zacks.com12 August 2024 Sentiment: NEUTRAL

Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
benzinga.com25 June 2024 Sentiment: POSITIVE

Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
Reuters06 May 2024 Sentiment: POSITIVE

Gossamer Bio announced a partnership with Chiesi Group to develop and market its drug seralutinib for various conditions related to blood pressure.

Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Zacks Investment Research07 March 2024 Sentiment: POSITIVE

Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

What type of business is Gossamer Bio?

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The company was registered in the state of Delaware on October 25, 2015, and is based in San Diego, California. They have 4 product candidates in clinical stage and several preclinical programs: GB001 (DP2 antagonist) - for the treatment of eosinophilic asthma and other allergic reactions. GB002 (PDGF receptor kinase inhibitor) - for the treatment of pulmonary arterial hypertension. GB004 (HIF-1 α stabilizer) - for the treatment of inflammatory bowel disease, including ulcerative colitis, Crohn's disease. GB1275 (CD11b modulator) - for the treatment of oncological diseases. None of their developed drugs have reached the commercial stage. All are in various stages of preclinical development.

What sector is Gossamer Bio in?

Gossamer Bio is in the Healthcare sector

What industry is Gossamer Bio in?

Gossamer Bio is in the Biotechnology industry

What country is Gossamer Bio from?

Gossamer Bio is headquartered in United States

When did Gossamer Bio go public?

Gossamer Bio initial public offering (IPO) was on 08 February 2019

What is Gossamer Bio website?

https://www.gossamerbio.com

Is Gossamer Bio in the S&P 500?

No, Gossamer Bio is not included in the S&P 500 index

Is Gossamer Bio in the NASDAQ 100?

No, Gossamer Bio is not included in the NASDAQ 100 index

Is Gossamer Bio in the Dow Jones?

No, Gossamer Bio is not included in the Dow Jones index

When was Gossamer Bio the previous earnings report?

No data

When does Gossamer Bio earnings report?

The next expected earnings date for Gossamer Bio is 05 March 2025